Lupus Erythematosus, Systemic
Conditions
Keywords
Skin and Connective Tissue Diseases, Connective Tissue Diseases, Immune System Diseases, Autoimmune Diseases, Musculoskeletal and connective tissue disorders
Brief summary
The goal of this clinical study is to learn about the long-term safety and tolerability of cenerimod in adult patients with moderate to severe symptoms of systemic lupus erythematosus. The main questions it aims to answer are: * Whether cenerimod causes any adverse effects ('side effects') when given on top of drugs already being given for systemic lupus erythematosus. * How well cenerimod works to reduce symptoms of systemic lupus erythematosus when taken for up to 5 years. Participants taking part in this study will have already taken part in another study, where they received either cenerimod or placebo (look-alike substance containing no active drug) for 1 year. In this clinical study approximately 680 participants will receive cenerimod (on top of drugs already being given for systemic lupus erythematosus) for up to 5 years.
Detailed description
Participants who completed the 12-month double-blind treatment period (cenerimod 4 mg or placebo) in either of the parent studies, ID-064A301 or ID-064A302, are eligible to participate in this extension study. All participants in this study will receive cenerimod 4 mg for up to a maximum of 60 months (5 years). All participants may additionally receive standard of care treatment for systemic lupus erythematosus, i.e., at least 1 of the following: oral corticosteroids, antimalarial drugs, or immunosuppressant drugs. The safety follow-up period starts on the day after the last dose of study treatment and ends after 6 months with the final study visit. Thus, the maximum duration of participation is 5.5 years. Data collected in this extension study will allow an assessment of whether the safety and tolerability profile of cenerimod established in the controlled parent studies remains the same after a longer period of treatment.
Interventions
DRUGCenerimod
Film-coated tablets at a dose of 4 mg.
Sponsors
Viatris Innovation GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Signed and dated informed consent form prior to any study-mandated procedure. 2. Participants with a diagnosis of systemic lupus erythematosus who: * Completed the 12-month double-blind treatment period of either of the parent studies (ID-064A301, ID-064A302). * Did not meet any study treatment stopping criteria during the parent study. * Completed the last scheduled visit of the parent study. Participants who did not complete the last scheduled visit for reasons beyond their control may be eligible for this study upon approval by the sponsor. 3. Women of child-bearing potential: * Negative pregnancy test at Visit 1. * Agreement to undertake monthly urine pregnancy tests from Visit 2 up to 6 months after study treatment discontinuation. * Agreement to use a highly effective method of contraception from Visit 1 up to 6 months after study treatment discontinuation.
Exclusion criteria
1. Poor compliance with study-mandated procedures during the parent study (ID-064A301 or ID-064A302), e.g., took less than 80% of the planned doses of double-blind study treatment; or did not attend a majority of the site visits, unless there was a medically justified reason as judged by the investigator. 2. Systemic lupus erythematosus driven renal disease, central nervous system lupus, or active severe or unstable neuropsychiatric systemic lupus erythematosus where, in the judgment of the investigator, protocol-specific systemic lupus erythematosus background therapy is insufficient, and the use of a more aggressive therapeutic approach or other treatments not permitted in the protocol is indicated. 3. Women of child-bearing potential planning to become pregnant up to the final study visit. 4. Judged not eligible to participate by the investigator, for any other reason. 5. Confirmed active or latent tuberculosis (applicable only if requested by local regulations).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment-emergent adverse events | Day 1 (post dose) to a maximum of 5.5 years | Occurrence of treatment-emergent adverse events up to the final study visit (maximum 5 years of study treatment plus 6-month safety follow-up period). |
| Serious adverse events | Day 1 (post dose) to a maximum of 5.5 years | Occurrence of serious adverse events up to the final study visit (maximum 5 years of study treatment plus 6-month safety follow-up period). |
| Adverse events of special interest | Day 1 (post dose) to a maximum of 5.5 years | Occurrence of adverse events of special interest up to the final study visit (maximum 5 years of study treatment plus 6-month safety follow-up period). Adverse events of special interest include the anticipated risks of treatment with cenerimod, known class effects, and events that may be related to systemic lupus erythematosus comorbidities, i.e., adverse events related to: * Effects on heart rate and rhythm * Hypotension * Hypertension * Cardiovascular * Hepatobiliary disorders / liver enzyme abnormalities * Pulmonary * Eye disorders * Infections * Skin malignancies * Non-skin malignancies |
Countries
Argentina, Brazil, Bulgaria, Chile, Colombia, Czechia, France, Georgia, Germany, Greece, Malaysia, Mexico, Peru, Philippines, Poland, Portugal, Puerto Rico, Romania, Serbia, South Africa, South Korea, Spain, Taiwan, Thailand, Ukraine, United States
Contacts
STUDY_DIRECTORClinical Trials
Viatris Innovation GmbH
Outcome results
None listed